Den Europæiske Union - dansk - EMA (European Medicines Agency)

axunio pharma gmbh - pirfenidon - idiopatisk lungefibrose - immunosuppressiva - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

viatris limited - imatinibmesilat - filmovertrukne tabletter - 100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - sitagliptinmalat - filmovertrukne tabletter - 25 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

viatris limited - imatinibmesilat - filmovertrukne tabletter - 400 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - sitagliptinmalat - filmovertrukne tabletter - 100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - sitagliptinmalat - filmovertrukne tabletter - 50 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - rivaroxaban - filmovertrukne tabletter - 15 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - rivaroxaban - filmovertrukne tabletter - 15 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochlorid - multipel sklerose, recidiverende-remitterende - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1)orpatients med hurtigt udviklende alvorlige relapserende remitterende multipel sklerose, der er defineret ved 2 eller flere invaliderende tilbagefald i et år, og med 1 eller flere gadolinium øge læsioner på hjernen mr-scanning eller en betydelig stigning i t2 læsion belastning i forhold til en tidligere de seneste mr -.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan ireland limited - fingolimod hydrochlorid - multipel sklerose, recidiverende-remitterende - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.